ReviewKidney diseases (Basel, Switzerland)2016
Homocysteine in Renal Injury.
Review in Kidney diseases (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Association of homocysteine with ankylosing spondylitis: a systematic review and meta-analysis.Advances in rheumatology (London, England) · 2021Pooled it
- Association Between Serum Homocysteine and Chronic Kidney Disease Severity in Vietnamese Outpatients With Type 2 Diabetes: A Cross-Sectional Study.Endocrinology, diabetes & metabolism · 2026Article
- Multiple Reaction Monitoring (MRM)-Based Targeted Kidney Metabolite Profiling of a Mouse Model of Hyperuricemia.Metabolites · 2026Article
- Estimated Glomerular Filtration Rate, Nutritional Factors, and Their Relationships With Homocysteine in Community-Dwelling Older Adults.Journal of nutrition and metabolism · 2026Article
- Sex-Differentiated Threshold Effects of Homocysteine Levels on CKD Risk in Patients with Hypertension and Coronary Artery Disease.Journal of inflammation research · 2026Article
- Evaluation of Total Homocysteine Levels in Relation to Abdominal Fat Mass and Traditional Cardiovascular Risk Factors in Overweight and Obese Adolescents.Life (Basel, Switzerland) · 2025Article
- Using Machine Learning to Detect Factors That Affect Homocysteine in Healthy Elderly Taiwanese Men.Biomedicines · 2025Article
- Hyperhomocysteinemia-Driven Ischemic Stroke: Unraveling Molecular Mechanisms and Therapeutic Horizons.Food science & nutrition · 2025Review
- Joint effects of elevated homocysteine levels and low eGFR on post-stroke cognitive impairment.Frontiers in neurology · 2025Article
- Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.Antioxidants (Basel, Switzerland) · 2024Review
- High methionine diet mediated oxidative stress and proteasome impairment causes toxicity in liver.Scientific reports · 2024Article
- Role of uranium toxicity and uranium-induced oxidative stress in advancing kidney injury and endothelial inflammation in rats.BMC pharmacology & toxicology · 2024Article
- U-shaped association between dietary niacin intake and chronic kidney disease among US elderly: a nationwide cross-sectional study.Frontiers in endocrinology · 2024Article
- Review
- Serum homocysteine concentration as a marker for advanced diabetic nephropathy in a cohort of elderly patients.BMC endocrine disorders · 2023Article
- Metabolomic Analysis ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders.Current cardiology reviews · 2023Article
- Association between homocysteinemia and mortality in CKD: A propensity-score matched analysis using NHANES-National Death Index.Medicine · 2022Article
- Indoxyl sulfate, homocysteine, and antioxidant capacities in patients at different stages of chronic kidney disease.Nutrition research and practice · 2022Article
- Resveratrol: A new approach to ameliorate hyperhomocysteinaemia-induced renal dysfunction.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHomocysteine (Hcy) is an intermediate of methionine metabolism. Hyperhomocysteinemia (HHcy) can result from a deficiency in the enzymes or vitamin cofactors required for Hcy metabolism. Patients with renal disease tend to be hyperhomocysteinemic, particularly as renal function declines, although the underlying cause of HHcy in renal disease is not entirely understood. SUMMARY: HHcy is considered a risk or pathogenic factor in the progression of chronic kidney disease (CKD) as well as the cardiovascular complications. KEY MESSAGES: In this review, we summarize both clinical and experimental findings that reveal the contribution of Hcy as a pathogenic factor to the development of CKD. In addition, we discuss several important mechanisms mediating the pathogenic action of Hcy in the kidney, such as local oxidative stress, endoplasmic reticulum stress, inflammation and hypomethylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.